Open original FDA record ↗Recall record
- FDA identifier
- Z-0653-2021
- Company in FDA record
- CryoLife, Inc.
- FDA record creation date
- Dec 21, 2020
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
On November 10, 2020, it was discovered that there are post- processing microbial culture test failures for other allografts, processed using a TRIS saline solution lot that was also used in processing allografts subjected to the recall.
Source facts
- Action
- A Recall notification letter titled "Urgent - Voluntary Human Tissue Recall" was sent to consignees via email or hand delivered by firm representatives. On 11-Nov-2020, 4 letters were delivered to consignees. On 12-Nov-2020, 2 letters were delivered to consignees. The letter instructs the consignee to complete and return the enclosed postcard affirming that they received the notification. The affected product should be quarantined and returned to CryoLife immediately, if it has not been implanted. CryoLife Field Representatives were to provide information necessary to arrange for the return of the affected product. If the product has been implanted and the consignee has questions or requires clarification, the consignee is to contact Dr. Gregory Ray, CryloLife Medical Director at 800-438-8285.
- Initiated
- 2020-11-10
- Root cause
- Material/Component Contamination
- Terminated
- 2021-10-26
- Distribution
- Distributed nationwide to GA, AZ, TX, MO, and OK.
- Recall number
- Z-0653-2021
- Recall status
- Terminated
- CDRH record ID
- 184759
- FDA record created
- 2020-12-21
- Recall event number
- 86890